James Anthony Torchia, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Anti-Idiotypic | 1 | 2016 | 349 | 0.500 |
Why?
|
| Vaccines, Synthetic | 1 | 2016 | 634 | 0.450 |
Why?
|
| Protein Engineering | 1 | 2016 | 540 | 0.420 |
Why?
|
| Lymphoma | 3 | 2016 | 1877 | 0.400 |
Why?
|
| Cancer Vaccines | 2 | 2016 | 1023 | 0.380 |
Why?
|
| Hashimoto Disease | 1 | 2023 | 97 | 0.210 |
Why?
|
| Graves Disease | 1 | 2023 | 242 | 0.200 |
Why?
|
| Tumor Escape | 1 | 2023 | 349 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 4 | 2023 | 9274 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2013 | 212 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2013 | 708 | 0.110 |
Why?
|
| Receptors, Immunologic | 2 | 2010 | 1423 | 0.100 |
Why?
|
| Lymphocyte Depletion | 2 | 2013 | 608 | 0.100 |
Why?
|
| Drug Design | 1 | 2016 | 1076 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2010 | 2916 | 0.090 |
Why?
|
| Osteoclasts | 3 | 2010 | 729 | 0.080 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2010 | 431 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 6314 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2013 | 2988 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 3772 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 3768 | 0.070 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2005 | 111 | 0.060 |
Why?
|
| Ovariectomy | 1 | 2007 | 661 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2727 | 0.060 |
Why?
|
| Immunologic Factors | 2 | 2013 | 1580 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2013 | 1241 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 931 | 0.060 |
Why?
|
| Chemokine CX3CL1 | 1 | 2023 | 58 | 0.060 |
Why?
|
| Receptors, Thyrotropin | 1 | 2023 | 45 | 0.060 |
Why?
|
| Bone Remodeling | 1 | 2007 | 575 | 0.060 |
Why?
|
| Mice | 9 | 2023 | 81183 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 625 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2005 | 648 | 0.050 |
Why?
|
| Chemotaxis | 1 | 2005 | 607 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2005 | 723 | 0.050 |
Why?
|
| Injections, Intralesional | 2 | 2013 | 276 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 2938 | 0.050 |
Why?
|
| Estrogens | 1 | 2007 | 1566 | 0.050 |
Why?
|
| Thyrotropin | 1 | 2023 | 849 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 6773 | 0.040 |
Why?
|
| Animals | 9 | 2023 | 168757 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 1526 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 2133 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 408 | 0.040 |
Why?
|
| Leucovorin | 1 | 2018 | 628 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2005 | 3200 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 426 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 684 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2023 | 2035 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2018 | 1619 | 0.030 |
Why?
|
| Receptors, OX40 | 1 | 2013 | 43 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 6386 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 1683 | 0.030 |
Why?
|
| Neoplasms | 1 | 2021 | 21683 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 8863 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2016 | 63114 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2005 | 11483 | 0.020 |
Why?
|
| Drug Costs | 1 | 2018 | 1105 | 0.020 |
Why?
|
| Humans | 7 | 2022 | 744343 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 5524 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 693 | 0.020 |
Why?
|
| src Homology Domains | 1 | 2010 | 364 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2013 | 541 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 2085 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2010 | 23403 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 1000 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 2716 | 0.020 |
Why?
|
| Middle Aged | 3 | 2018 | 213383 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1915 | 0.020 |
Why?
|
| Female | 6 | 2018 | 380194 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2009 | 623 | 0.020 |
Why?
|
| Rats | 1 | 2023 | 24260 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 3689 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 5391 | 0.020 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2005 | 79 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2005 | 193 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 2386 | 0.020 |
Why?
|
| Interleukin-3 | 1 | 2005 | 444 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 3701 | 0.010 |
Why?
|
| RANK Ligand | 1 | 2005 | 326 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 2007 | 582 | 0.010 |
Why?
|
| Granulocytes | 1 | 2005 | 548 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 657 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 16689 | 0.010 |
Why?
|
| Uterus | 1 | 2007 | 711 | 0.010 |
Why?
|
| Cell Division | 1 | 2010 | 4568 | 0.010 |
Why?
|
| Organ Size | 1 | 2007 | 2252 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 873 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 3557 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8642 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 21827 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8436 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 2958 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 1848 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11524 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2013 | 4445 | 0.010 |
Why?
|
| RNA Interference | 1 | 2005 | 2889 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2007 | 2575 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 7023 | 0.010 |
Why?
|
| Monocytes | 1 | 2005 | 2596 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 12354 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 4479 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15997 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 2924 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 13408 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 57776 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 4554 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 16365 | 0.010 |
Why?
|
| Aged | 2 | 2018 | 163280 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2007 | 14557 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 5021 | 0.010 |
Why?
|
| Male | 3 | 2018 | 350118 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 8949 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 29063 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 19229 | 0.010 |
Why?
|
| Adult | 1 | 2010 | 214055 | 0.000 |
Why?
|